Trump’s divisive FDA vaccine regulator self-destructs, will exit agency (again)

Vinay Prasad is set to leave the Food and Drug Administration (FDA) for the second time, as confirmed by FDA Commissioner Marty Makary in a social media announcement. Prasad's exit, scheduled for April, comes after a turbulent year marked by contentious decisions that have sparked significant debate within the agency and beyond. During his tenure, Prasad faced scrutiny for several controversial actions, including a surprising rejection of an mRNA vaccine that was later overturned, and a call for additional clinical trials on a gene therapy for Huntington's disease that many viewed as setting impractical new standards. His public criticism of UniQure, the developer of that gene therapy, alongside allegations of creating a toxic work environment for FDA staff, has contributed to a climate of unrest within the agency. The impact of Prasad's decisions has resonated throughout the biotechnology and pharmaceutical sectors, as well as among patient advocacy groups. Following the announcement of his departure, financial analysts reacted positively, suggesting his exit represents a significant victory for the biotech industry, particularly for companies involved in rare diseases. For example, UniQure's stock surged approximately 25% after the news broke. This marks Prasad's second exit from the FDA during the Trump administration. His first departure occurred in July, following backlash over his management of a gene therapy for Duchenne muscular dystrophy and criticism from far-right activist Laura Loomer. Although he was reinstated shortly thereafter, his qualifications for his roles at the FDA have been questioned. Prasad, a professor at the University of California, San Francisco, and a practicing hematologist-oncologist, entered the FDA without regulatory experience or specific expertise in vaccines or gene therapies. His visibility in regulatory discussions largely grew from his online critiques of pandemic-related health policies, including those surrounding COVID-19 vaccinations.